APA (7th ed.) Citation

Knox, J., McNamara, M., Goyal, L., Doherty, M., Cosgrove, D., Springfeld, C., . . . Valle, J. (2020). 80TiP Global phase III study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide: 121). Annals of Oncology, 31, S272. https://doi.org/10.1016/j.annonc.2020.08.058

Chicago Style (17th ed.) Citation

Knox, J.J, et al. "80TiP Global Phase III Study of NUC-1031 Plus Cisplatin Vs Gemcitabine Plus Cisplatin for First-line Treatment of Patients with Advanced Biliary Tract Cancer (NuTide: 121)." Annals of Oncology 31 (2020): S272. https://doi.org/10.1016/j.annonc.2020.08.058.

MLA (9th ed.) Citation

Knox, J.J, et al. "80TiP Global Phase III Study of NUC-1031 Plus Cisplatin Vs Gemcitabine Plus Cisplatin for First-line Treatment of Patients with Advanced Biliary Tract Cancer (NuTide: 121)." Annals of Oncology, vol. 31, 2020, p. S272, https://doi.org/10.1016/j.annonc.2020.08.058.